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Rationale: An elevated level of plasma LDL (low-density lipoprotein) is an 
established risk factor for cardiovascular disease. Recently, we reported that the 
(pro)renin receptor ([P]RR) regulates LDL metabolism in vitro via the LDLR (LDL 
receptor) and SORT1 (sortilin-1), independently of the renin–angiotensin system. 
Objectives: To investigate the physiological role of (P)RR in lipid metabolism in 
vivo. 
Methods and Results: We used N-acetylgalactosamine modified antisense 
oligonucleotides to specifically inhibit hepatic (P)RR expression in C57BL/6 mice 
and studied the consequences this has on lipid metabolism. In line with our earlier 
report, hepatic (P)RR silencing increased plasma LDL-C (LDL cholesterol). 
Unexpectedly, this also resulted in markedly reduced plasma triglycerides in a 
SORT1-independent manner in C57BL/6 mice fed a normal- or high-fat diet. In 
LDLR-deficient mice, hepatic (P)RR inhibition reduced both plasma cholesterol and 
triglycerides, in a diet-independent manner. Mechanistically, we found that (P)RR 
inhibition decreased protein abundance of ACC (acetyl-CoA carboxylase) and PDH 
(pyruvate dehydrogenase). This alteration reprograms hepatic metabolism, leading to 
reduced lipid synthesis and increased fatty acid oxidation. As a result, hepatic (P)RR 
inhibition attenuated diet-induced obesity and hepatosteatosis. 
Conclusions: Collectively, our study suggests that (P)RR plays a key role in energy 
homeostasis and regulation of plasma lipids by integrating hepatic glucose and lipid 
metabolism.   
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Introduction:  
Elevated plasma LDL (low-density lipoprotein) levels are a major risk factor for 
developing atherosclerosis and ensuing ischemic cardiovascular disease, a leading 
cause of worldwide death. LDL, which is derived by peripheral lipolysis of VLDL 
(very-low-density lipoprotein), is primarily cleared from the circulation in the liver 
via the LDLR (LDL receptor) pathway1,2. Hence, plasma LDL levels are determined 
by the dynamic balance between hepatic VLDL secretion and LDL clearance. 
 
VLDL particles are formed by lipidation of apo (apolipoprotein) B100, the core 
protein of VLDL, in the endoplasmic reticulum and Golgi apparatus3. The assembly 
of VLDL particles depends on apo B100 production and cellular availability of 
triglycerides. Accordingly, genetic mutations in apo B100 are associated with altered 
VLDL secretion and plasma LDL levels4–6. Overexpression of apo B100 results in 
increased VLDL secretion and plasma LDL levels in rabbits7. Similarly, the activity 
of enzymes involved in de novo lipid biosynthesis also affects VLDL assembly and 
secretion8,9. For example, impaired loading of triglycerides into nascent VLDL 
particles, aused by mutations in the MTP (microsomal triglyceride carrier protein), 
results in defective VLDL secretion10. Disturbed LDL clearance can increase plasma 
LDL levels and risk for cardiovascular diseases. In line with this, loss-of function 
LDLR mutations are associated with elevated plasma LDL levels and cardiovascular 
risk11–13. Recently, GWAS studies have identified single-nucleotide polymorphisms 
mapping to 1p13.3 that strongly associated with plasma LDL levels and coronary 
heart disease14–19. Subsequent mechanistic studies revealed that SORT1 (sortilin-1), 
located within the 1p13.3 region, is a novel regulator of LDL metabolism20–22. 
Overexpression of SORT1 increases LDL clearance and decreases plasma LDL 
levels16,21,22, whereas SORT1 deficiency reduces cellular LDL uptake in vitro and 
LDL clearance in vivo22,23. In addition, SORT1 also plays a role in VLDL secretion. 
Overexpressing SORT1 promotes ApoB degradation via an endolysosome-dependent 
route and hence reduces VLDL secretion and plasma triglyceride levels22. 
Controversially, mice deficient for SORT1 also display reduced VLDL secretion and 
triglyceride levels20,22. These opposing results highlight the complex, and not yet fully 
elucidated, role of SORT1 in lipoprotein metabolism. The (pro)renin receptor ([P]RR) 
interacts with renin/prorenin (denoted as [pro]renin) at supraphysiological 
concentrations that are even several orders of magnitude higher than 
(patho)physiological concentrations, questioning the physiological relevance of the 
(P)RR–(pro)renin interaction24,25. Recently, the (P)RR was reported to play a role in 
Wnt/β-catenin signaling pathway, vacuolar H+-ATPase integrity, and T-cell 
development, independently of (pro)renin26–30. Moreover, we have recently identified 
the (P)RR as a SORT1-interacting protein31 and demonstrated that silencing (P)RR 
expression in hepatocytes in vitro reduces protein abundance of SORT1 and LDLR 
post-transcriptionally, and consequently cellular LDL uptake. To understand the role 
of the (P)RR in lipoprotein metabolism in vivo, we studied here the consequence of 
hepatic (P)RR silencing on lipoprotein metabolism. We report that hepatic loss of 
(P)RR in mice results in a SORT1-dependent increase in plasma LDL levels, but 
unexpectedly also in a reduction in plasma triglycerides that was SORT1 independent 
that resulted from altered metabolic reprogramming of hepatocytes. Our study thus 
highlights hepatic (P)RR as a crucial regulator of energy and lipid metabolism. 
 
Results: 
 
Inhibiting Hepatic (P)RR Reduced Both Hepatic LDL Clearance and VLDL 
Secretion 
We have previously reported that (P)RR inhibition attenuates cellular LDL uptake by 
reducing LDLR and SORT1 protein abundance in hepatocytes31. To understand the 
role of hepatic (P)RR in lipoprotein metabolism in vivo, we used 
N-acetylgalactosamine modified antisense oligonucleotides to inhibit hepatic (P)RR 
expression. At a dose of 3.0 mg kg−1 wk−1, N-acetylgalactosamine (P)RR antisense 
oligonucleotide (G-[P]RR) potently reduced (P)RR expression in liver, but had no 
effects on its expression in other major organs, including heart, kidney, intestine, 
spleen, and different adipose tissues (Online Figure IA and IC through IF). In line 
with our previous report, inhibiting the (P)RR specifically reduced hepatic LDLR and 
SORT1 protein levels without affecting their transcript levels (Online Figure IB). As a 
result of reduced hepatic LDLR and SORT1 protein abundance, (P)RR inhibition 
elevated plasma cholesterol levels in normal diet (ND)–fed mice, primarily by 
increasing cholesterol content in IDL (intermediate-density lipoprotein)/LDL 
fractions (Figure 1A and 1B). Because plasma LDL-C concentrations reflect the 
balance between hepatic LDL clearance and VLDL secretion, we then investigated 
the effects of (P)RR inhibition on LDL clearance and hepatic VLDL output. In line 
with decreased LDLR and SORT1, inhibiting hepatic (P)RR led to attenuated 
clearance of injected Dil-labeled human LDL (Figure 1C). Unexpectedly, (P)RR 
inhibition also significantly decreased plasma triglyceride concentrations (Figure 1D), 
a finding that could be attributed to reduced hepatic VLDL secretion (Figure 1E). 
 
We then asked if silencing (P)RR in hepatocytes could aggravate 
hypercholesterolemia in C57BL/6 mice fed a high-fat diet (HFD). Like in ND-fed 
mice, 1 week after (P)RR inhibition, plasma cholesterol levels were 3- to 4- fold 
higher than those measured in N-acetylgalactosamine control antisense 
oligonucleotide (G-control)–injected mice (Figure 2A). This elevation was primarily 
attributed to a marked increase in cholesterol content in the IDL/LDL fraction (Figure 
2B). Notably, (P)RR inhibition also increased cholesterol contents in the VLDL 
fraction and reduced cholesterol contents in the HDL (high-density lipoprotein) 
fraction. Unexpectedly, within 2 weeks, plasma cholesterol levels of G-(P)RR–
injected mice were normalized and similar to those in the saline-injected or 
G-control–injected mice (Figure 2A and 2C; Online Figure IG). This contrasts with 
the sustained increase in plasma cholesterol levels in C57BL/6 mice fed with ND 
(Online Figure IH). Nevertheless, (P)RR inhibition in HFD-fed mice reduced hepatic 
LDL clearance and VLDL secretion (Figure 2D and 2E). Plasma triglycerides and 
VLDL triglycerides were both lower in G-(P)RR–injected mice when compared with 
saline or G-control–injected mice (Figure 2F and 2G), thus mimicking the pattern 
seen under ND feeding. Importantly, plasma LPL (lipoprotein lipase) activity was not 
affected by hepatic (P)RR inhibition (Figure 2H). This excludes the possibility that 
increased triglyceride hydrolysis underpins reduced levels of plasma triglycerides in 
(P)RR-silenced mice. 
 
 
Figure 1. Inhibiting hepatic (pro)renin receptor ([P]RR) induces hypercholesterolemia by reducing 
hepatic LDL (low-density lipoprotein) clearance in normal diet (ND)–fed C57BL/6 mice. 
Eight-week-old male C57BL/6 mice were injected with either saline (blue), G-control (magenta), or 
G-(P)RR (green) intraperitoneally. Mice were euthanized after 7 days, and blood samples were 
collected for (A) determining circulating levels of cholesterol (n=12–18 per group). Each bar and error 
represent the mean±SEM; ***P<0.001, or (B) pooled plasma samples were loaded on FPLC (fast 
protein liquid chromatography) for lipoprotein fractionation analysis, and cholesterol content in each 
fraction was determined. C, Seven days after injection, mice (n=6 per group) were injected with 50 μg 
Dil-labeled human LDL. Blood samples were drawn retro-orbitally at the indicated time points, and the 
Dil-LDL was determined. Each point represents the mean±SEM, and the area under curve (AUC) was 
constructed for each group and used to compare the difference in LDL clearance.***P<0.001. D, Blood 
was collected as in (A) and used to determine plasma triglyceride levels. n=12–18 per group; Each bar 
and error represent the mean±SEM. ***P<0.001. E, Seven days after injection, mice (n=6 per group) 
were fasted for 6 hours and injected with Pluronic F127 to inhibit lipoprotein lipase. Blood samples 
were drawn retro-orbitally at the indicated time points, and the concentration of triglycerides was 
determined. The mean VLDL (very-low-density lipoprotein) secretion for saline-injected, G-control–
injected, or G-(P) RR–injected mice is 474±16, 460±14, and 342±10 mg/dL•h, respectively. The AUC 
was calculated for individual mice and used to compare the differences in the rate of VLDL secretion.  
***P<0.001; G-control vs G-(P)RR. HDL indicates high-density lipoprotein; and IDL, 
intermediate-density lipoprotein. 
 
 
Figure 2. Inhibiting hepatic (pro)renin receptor ([(P]RR) does not result in hypercholesterolemia in 
high-fat diet (HFD)–fed C57BL/6 mice. Eight-week-old male C57BL/6 mice were injected with either 
saline (blue), G-control (magenta), or G-(P)RR (green), and fed an HFD for 4 weeks. A, Plasma 
cholesterol concentrations were determined weekly, and each point represents the mean±SEM. n=10 
per group; ***P<0.001; G-control vs G-(P)RR. B, C, Pooled plasma samples were collected after the 
(B) first week of diet, or (C) after 4 weeks of diet, and the lipoprotein distribution was determined. The 
cholesterol content in each fraction was determined and is plotted. D, Two weeks after start of HFD 
diet, mice (n=6 per group) were injected with 50 μg Dil-labeled human LDL, and LDL clearance was 
assessed. Each point represents the mean±SEM, and the area under curve (AUC) was constructed for 
each treatment and used to compare the differences in LDL (low-density lipoprotein) clearance. 
*P<0.05. E, Two weeks after (P)RR inhibition, mice were fasted for 6 hours, and VLDL 
(very-low-density lipoprotein) secretion was assessed (n=6 per group) by injecting mice with Pluronic 
F127 to inhibit lipoprotein lipase. Blood samples were drawn retro-orbitally at the indicated time points, 
and the concentration of triglycerides was determined, and the AUC was calculated and used to 
compare the differences in the rate of VLDL secretion. **P<0.01; G-control vs G-(P)RR. F, G, Plasma 
triglyceride levels were analyzed in samples collected after 4 weeks of HFD. Each bar represents the 
mean±SEM, n=10 per group. 
***P<0.001, or (G) pooled plasma samples were analyzed by FPLC (fast protein liquid 
chromatography). H, Plasma LPL (lipoprotein lipase) activity was determined for mice were injected 
with G-control or G-(P)RR and fed HFD for 4 weeks. n=9 per group. HDL indicates high-density 
lipoprotein; IDL, intermediate-density lipoprotein; and N.S., not significant. 
 
Because SORT1 deficiency in vivo reduces VLDL secretions and plasma 
triglycerides and (P)RR silencing decreases SORT120,22,31, we wondered if the effect 
of (P)RR inhibition on hepatic lipid output is SORT1 dependent. To address this 
possibility, we studied plasma lipid levels in (P) RR-silenced mice in which we 
overexpressed hSORT1 (human SORT1). Exogenous hSORT1 protein was detected 
in liver, and hSORT1 partially rescued the (P)RR inhibition– induced LDLR protein 
reduction (Online Figure II). Given that SORT1 itself is a clearance receptor for 
LDL20–22, it is not surprising that hSORT1 overexpression reversed the (P) RR 
inhibition–induced increase in plasma cholesterol levels, primarily by decreasing the 
cholesterol content in the VLDL and IDL/LDL fractions (Figure 3A and 3B). 
However, hSORT1 overexpression did not prevent the reduction in plasma 
triglycerides caused by (P)RR inhibition (Figure 3C), implying that (P)RR inhibition 
reduced plasma triglycerides in a SORT1-independent manner. 
 
Hepatic (P)RR Inhibition Reduced Plasma Cholesterol Levels in LDLR-Deficient 
Mice 
As (P)RR affects both hepatic LDL clearance and VLDL secretion, it is possible that 
(P)RR has a differential role in governing plasma cholesterol levels under distinct diet 
condiions. Under ND, LDL clearance may govern plasma cholesterol levels, whereas 
under HFD, VLDL secretion may become more prominent in determining plasma 
cholesterol levels. To address this issue, we tested the effects of hepatic (P)RR 
inhibition on plasma cholesterol levels in mice with impaired LDL clearance by 
injecting adeno-associated virus expressing the gain-of-function PCSK9 (proprotein 
convertase subtilisin/kexin type 9) D377Y mutant32,33 and in LDLR-/-mice. As 
expected, injecting C57BL/6 mice with the PCSK9 D377Y–encoding 
adeno-associated virus led to a marked in-crease in the circulating levels of LDL-C 
(from 76.74±1.72 to 167.3±2.27 mg/dL, n=39). We subsequently injected these mice 
with either saline, G-control, or G-(P)RR for 4 weeks and fed either ND or HFD. We 
found that after this treatment period, (P)RR inhibition reduced plasma cholesterol 
levels in both ND- and HFD-fed mice, despite the lack of functional LDLR-mediated 
clearance (Figure 4A through 4D). Similarly, inhibiting hepatic (P)RR in 
LDLR-/-mice induced a sustained decrease in plasma cholesterol levels independent 
of diet (Online Figure IIIA and IIIB).  
 
Figure 3. SORT1 (sortilin-1) overexpression prevents PRR-dependent hypercholesterolemia, but does 
not affect reduction in plasma triglycerides. Eight-week-old male C57BL/6 mice were injected with 
G-control or G-(pro)renin receptor ([P]RR) intraperitoneally and subsequently injected with either 
adenovirus carrying GFP (green fluorescent protein; Ad-GFP) or adenovirus carrying human SORT1 
(Ad-SORT1) via the tail vein. Mice were fed with normal diet (ND) or high-fat diet (HFD) for 1 week 
and (A) plasma cholesterol levels were determined. Each bar represents the mean±SEM (n=6 per 
group). **P<0.01; ***P<0.001. Alternatively, (B) lipoprotein composition in pooled plasma samples 
was analyzed by fractionation. C, Plasma was collected as in (A) and analyzed for triglyceride content. 
Each bar and error represent the mean±SEM (n=6 per group). **P<0.01. HDL indicates high-density 
lipoprotein; IDL, intermediate-density lipoprotein; LDL, low-density lipoprotein; and VLDL, 
very-low-density lipoprotein. 
 
These results confirm that LDL clearance is more dominant than VLDL secretion in 
determining circulating LDL levels in mice fed ND. Similar to the observation in 
wild- 
type C57BL/6 mice, plasma triglycerides and VLDL-associated triglycerides were 
reduced by (P)RR inhibition under ND or HFD feeding (Figure 4E through 4H), in 
PCSK9-induced LDLR-deficient mice. Moreover, in LDLR-/-mice, 
hypertriglyceridemia was prevented by hepatic (P)RR inhibition (Online Figure IIIC 
and IIID). We reasoned that if (P)RR inhibition primarily affects lipid export 
pathways, we should observe lipid accumulation in liver, especially under HFD 
feeding. However, we found that hepatic lipid levels were also reduced by (P)RR 
inhibition (Figure 4I through 4K; Online Figure IV), implying that the reduced plasma 
lipid levels are not the result of impaired lipid secretion. 
 
       
Figure 4. Hepatic (pro)renin receptor ([P]RR) inhibition in the absence of LDLR (low-density 
lipoprotein receptor) reduces plasma lipid levels and hepatic lipid deposition. Eight-week-old male 
C57BL/6 mice were injected intraperitoneally with 10×1010 genomic copies of mouse PCSK9 
(proprotein convertase subtilisin/kexin type 9) D377Y adeno-associated virus (AAV), and fed with 
normal diet (ND) for 4 weeks. Subsequently, mice were injected with either saline (blue), G-control 
(magenta), or G-(P)RR (green) and fed with ND or high-fat diet (HFD) for an additional 4 weeks. A–D, 
Plasma cholesterol levels and lipoprotein profiles at the end of study were determined for ND-fed (A, 
B) and HFD-fed (C, D) mice. E–H, Plasma triglycerides and lipoprotein distribution were determined 
for ND-fed (E, G) and HFD-fed (F, H) mice. (n=6 per group.) **P<0.01; ***P<0.001; G-control vs 
G-(P)RR. I, Representative images of Oil Red O–stained liver samples from above-indicated mice fed 
with ND or HFD for 4 weeks. Scale bar=100 μm. J, K, Lipids were extracted from liver samples and 
analyzed for triglycerides and cholesterol levels. *P<0.05; G-control vs G-(P)RR. HDL indicates 
high-density lipoprotein; IDL, intermediate-density lipoprotein; LDL, low-density lipoprotein; and 
VLDL, very-low-density lipoprotein. 
 
Hepatic (P)RR Inhibition Attenuated Diet-Induced Obesity and Improved 
Metabolic Disorders 
(P)RR inhibition resulted in decreased hepatic VLDL secretion without concomitant 
hepatic lipid accumulation. This could point toward (P)RR regulating hepatic lipid 
biosynthesis, an important facet of fatty liver disease and obesity34. We therefore 
questioned whether hepatic (P)RR inhibition can ameliorate diet-induced fatty liver 
disease and obesity. To address this, we inhibited hepatic (P)RR expression in 
C57BL/6 mice fed an HFD for 14 weeks. In line with our hypothesis, loss of hepatic 
(P)RR attenuated diet-induced obesity in C57BL/6 mice (Figure 5A). Body 
composition analyses using EchoMRI revealed that inhibiting hepatic (P)RR lowered 
fat weight of the mice, but did not affect the weight of lean mass (Figure 5B; Online 
Figure VA). Furthermore, the size of the livers and white adipose tissues of 
G-(P)RR-injected mice were smaller than control mice (Figure 5C and 5D). Under 
HFD, lipid accumulates in liver and increases liver weight. Mean liver weight of 
saline-injected or G-control–injected mice was ≈2 g, which was nearly twice the mean 
liver weight (1.07±0.02 g; n=12; P<0.001) of ND-fed C57BL/6 mice at same age (22 
weeks old). Hepatic (P)RR inhibition attenuated HFD-induced liver weight gain and 
prevented abnormal lipid deposition in the liver (Figure 5E and 5F). Liver/body 
weight ratios of G-(P)RR-injected mice were also significantly lower than that of 
G-control–injected mice and resembled the ratio of ND-fed C57BL/6 mice at the 
same age (Online Figure VB). Moreover, mice in which hepatic (P)RR was inhibited 
had smaller adipocytes in inguinal white adipose tissues (Online Figure VC), but 
normal brown adipose tissues weight (Figure 5D). In agreement with reduced adipose 
tissues, plasma leptin concentrations were also reduced by hepatic (P)RR inhibition 
(Online Figure VD). However, plasma adiponectin concentrations were unaltered by 
(P)RR inhibition despite the marked reduction in adipose tissue weight (Online Figure 
VE), likely because of increased expression of adiponectin in white adipose tissues 
(Online Figure IC and IE). This suggests that hepatic (P)RR inhibition can indirectly 
affect adipokine secretion by adipose tissues, thereby contributing to improved 
metabolic control. 
 
Accompanied by less body weight gain, fasting blood glucose concentrations were 
reduced by (P)RR inhibition (Online Figure VF), which also improved glucose 
tolerance and lowered plasma insulin levels (Online Figure VG and VH). Plasma AST 
(aspartate aminotransferase), ALT (alanine aminotransferase), and AST/ALT ratio 
indicate that (P)RR inhibition did not cause liver damage (Online Figure VI). In 
addition, H&E (hematoxylin and eosin) staining also revealed improved liver 
morphology by (P)RR inhibition (Figure 5E). Cumulative food intake of the mice 
during the 14-week experimental period was also recorded. G-(P)RR–injected mice 
consumed slightly less food than saline or G-control–injected mice, but when 
corrected for their body weight, their food consumption was actually higher (Online 
Figure VJ), suggesting that the reduced body weight gain is not because of reduced 
food intake. In addition, we did not observe any difference in blood pressure or heart 
rate among saline-injected, G-control–injected, or G-(P)RR– injected mice (Online 
Figure VK and VL), suggesting that the activity of the autonomic nervous system was 
not affected. We then monitored oxygen consumption and physical activity of the 
mice using metabolic cages. Inhibiting hepatic (P)RR increased oxygen consumption 
and 24-hour respiratory quotient of the mice, implying increased catabolism of energy 
sources (Figure 5G). Yet, physical activities of the mice were not different (Online 
Figure VM). Collectively, these results support the beneficial metabolic effects of 
(P)RR inhibition. 
 
 
Figure 5. Hepatic (pro)renin receptor ([P]RR) inhibition attenuates diet-induced obesity and metabolic 
dysregulation. Eight-week-old mice were injected with saline (blue), G-control (magenta), or G-(P)RR 
(green) and fed a high-fat diet (HFD) for 14 weeks. (n=10 per group.) A, Body weight was monitored 
during the study period and each point and error represent the mean±SEM. ***P<0.001. Representative 
picture showing that G-(P)RR–injected mice are leaner than control mice. B, Fat and lean mass were 
measured by EchoMRI. Each bar and error represent the mean±SEM. ***P<0.001. C, Liver weight, 
and representative pictures showing G-(P)RR–treated mice have less fatty liver. **P<0.01. D, Weight 
and representative picture of different adipose tissue depots. Brown fat tissue of saline and G-control–
injected mice were surrounded with white fat which was removed to give a correct estimation of the 
weight of the brown fat. ***P<0.001. E, Representative images of Oil Red O (ORO) and H&E 
(hematoxylin and eosin) staining of the livers (scale bar=200 μm). F, Hepatic lipids were extracted and 
measured. *P<0.05; G-control vs G-(P)RR. G, Oxygen consumption and 24-h average respiratory 
quotient (RQ) of G-control–injected and G-(P)RR–injected mice was monitored with a metabolic 
monitoring system 4 days before euthanize. n=8 per group. BAT indicates brown adipose tissue; 
eWAT, epididymal white adipose tissue; iWAT, inguinal white adipose tissue; N.S., not significant; 
and rWAT, retroperitoneal white adipose tissue. 
 
Inhibiting the (P)RR Upregulated Genes Involved in Fatty Acid Oxidation 
Currently recognized functions of the (P)RR are not linked with lipid biosynthesis and 
energy homeostasis. To understand how (P)RR may regulate these processes, we 
transcriptionally profiled mice after (P)RR inhibition. Male mice (8 weeks old) were 
injected with either saline or G-(P)RR for 5 days, and liver samples were collected 
and extracted for total RNA and RNAseq analysis. We identified that (P)RR 
inhibition led to up- and downregulation of 199 genes and 202 genes, respectively 
(Online Table III). Gene ontology enrichment analysis revealed that metabolic 
pathways, including fatty acid (FA) degradation and elongation, were strongly 
affected by (P)RR inhibition (Online Figure VIA and VIB). Among the affected genes, 
several genes involved in FA β-oxidation, such as Hadha, Acaa2, Acadvl, and Acadl, 
were upregulated by (P)RR inhibition, as confirmed by quantitative polymerase chain 
reaction (Online Figure VII). As such, increased FA β-oxidation may contribute to 
increased oxygen consumption and reduced hepatic lipid content. 
 
Inhibiting (P)RR Reduced Protein Abundance of ACC and PDH 
To complement the RNA sequencing analysis and to better understand the function(s) 
of the (P)RR, we next performed comparative quantitative proteomics to identify 
hepatic proteins which are affected by (P)RR inhibition. Through this unbiased 
approach, we identified 191 and 116 proteins that were down- and upregulated, 
respectively, after (P)RR inhibition during feeding of either ND or HFD (Online 
Table IV). As reported previously, LDLR protein abundance was decreased by (P)RR 
inhibition (Online Table IV), validating the effectiveness of this approach to identify 
proteins with altered abundance. Gene ontology enrichment analyses revealed that 
proteins involved in lipid biosynthesis, lipid metabolism, and cholesterol metabolism 
were markedly affected by (P)RR inhibition (Online Figure VIC and VID). Among 
the identified proteins, PDH (pyruvate dehydrogenase), ACCα (acetyl-CoA 
carboxylase α), and ACCβ were markedly decreased. PDH is the enzyme responsible 
for converting pyruvate to acetyl-CoA and is a central metabolic node35. ACC 
catalyzes the formation of malonyl-CoA, an essential substrate for FA synthesis and a 
potent inhibitor of FA oxidation36. ACC is crucial in determining lipid storage and 
overall energy metabolism.37 Thus, reduced PDH and ACC may contribute to 
increased FA oxidation and decreased lipid synthesis. To confirm this, we examined 
ACCα/β and PDH protein abundance in the liver of saline-injected, G-control–
injected, or G-(P)RR–injected C57BL/6 mice fed with HFD for 14 weeks. 
Corroborating the proteomic-based approach, hepatic ACCα/β, PDHA ­(pyruvate 
dehyrogenase E1 component subunit α), and PDHB (pyruvate dehydrogenase E1 
component subunit β) were reduced by ≈40% to 60% after hepatic (P)RR inhibition 
(Figure 6A), whereas the transcript abundance of ACCα/β, PDHA, and PDHB 
remained unaltered (Online Figure VII). Inhibiting the (P)RR in human hepatoma 
HepG2 cells with siRNAs also reduced protein abundances of ACCα/β, PDHA, and 
PDHB (Online Figure VIIIA), suggesting that this outcome is conserved in both 
mouse and humans. The (P)RR knockdown– induced reduction in ACCα/β protein 
abundance was partially reversed by the lysosome inhibitor bafilomycin A1, but was 
not affected by the autophagy inhibitor 3-methyladenine or the proteasome inhibitor 
MG-132 (Online Figure VIIIB), suggesting accelerated lysosome-dependent 
degradation of ACCα/β by (P)RR inhibition. In contrast, bafilomycin A1, 
3-methyladenine, and MG-132 were unable to rescue (P)RR knockdown–induced 
reduction in PDHA and PDHB, implying that a different mechanism underlies the 
control of these proteins by (P)RR. 
 
(P)RR Inhibition Reduced Cellular Acetyl-CoA Abundance and FA Synthesis in 
Hepatocytes 
Collectively, our results suggest that by reducing protein abundance of PDH, (P)RR 
inhibition reduces pyruvate to acetyl-CoA conversion and therefore reduces cellular 
acetyl-CoA production from glucose. Lower cellular acetyl-CoA levels will limit 
cellular FA and cholesterol synthesis. This biosynthetic block will be compounded by 
reduced ACC abundance, which will further limit FA synthesis. To test this 
hypothesis, we first measured relevant hepatic metabolites in mice injected with 
saline, G-control, or G-(P)RR and fed with HFD for 14 weeks. As expected, G-(P) 
RR–injected mice displayed hepatic pyruvate accumulation (Figure 6B), increased 
plasma pyruvate and lactate concentrations (Figure 6C and 6D), and decreased 
hepatic PDH activity (Figure 6E). Nevertheless, despite these changes, hepatic 
acetyl-CoA concentrations were unaltered by (P)RR inhibition (Figure 6F). Yet 
importantly, cellular acetyl-CoA levels in isolated mouse primary hepatocytes in 
which (P)RR was inhibited using G-(P)RR antisense oligonucleotide were reduced 
(Figure 6G). Similarly, acetyl-CoA levels were decreased by (P)RR inhibition in 
HepG2 cells, combined with a decrease in cellular PDH activity, increased cellular 
pyruvate concentrations and medium lactate concentrations, and reduced cellular lipid 
levels (Online Figure VIIIC through VIIIG). These data support our hypothesis and 
simultaneously suggest that in vivo, alternative sources, especially FAs supply, are 
available to overcome reduced pyruvate to acetyl-CoA conversion. This may also 
explain why acetyl-CoA levels were not reduced in the liver, as they were in HepG2 
cells and primary hepatocytes. It is plausible that increased FA oxidation provides 
additional acetyl-CoA to compensate the increased energetic demand, which could 
also explain the increased oxygen consumption observed in G-(P)RR–injected mice. 
Therefore, we examined if (P)RR inhibition affects the oxygen consumption rate in 
mouse primary hepatocytes and HepG2 cells. As expected, inhibiting the (P)RR 
significantly increased basal oxygen consumption rate by ≈50% in mouse primary 
hepatocytes (Figure 6G) and ≈30% in HepG2 cells (Online Figure VIIIH), and 
implying increased energy expenditure and utilization of high oxygen–consuming 
fuels such as FA. To fully understand the mechanism, we further examined cellular 
fuel dependency on long-chain FA in mouse primary hepatocytes and HepG2 cells. In 
the presence of 50 µmmol/L oleic acid, long-chain FA accounted for ≈20% to 30% 
oxidized fuels (glucose, glutamine, and long-chain FA together) in control cells, 
whereas it accounted for >40% oxidized fuels in primary mouse hepatocytes and 
HepG2 cells with (P)RR inhibited (Figure 6H; Online Figure VIIII). These data 
suggest that reduced acetyl-CoA supply from pyruvate is compensated by increased 
FA oxidation, as a mechanism to sustain cellular energy needs. 
 
 
Figure 6. Inhibiting the (pro)renin receptor ([P]RR) reduces PDH (pyruvate dehydrogenase) and ACC 
(acetyl-CoA carboxylase) protein abundance and activity. A, Representative blot of liver samples from 
mice injected with saline, G-control, or G-(P)RR, and fed a high-fat diet (HFD) for 14 weeks. The 
protein abundance of PDHA (pyruvate dehyrogenase E1 component subunit α), PDHB (pyruvate 
dehydrogenase E1 component subunit β), and ACCα/β was quantified and normalized to the level of 
β-actin in the same lysate. (n=6 per group); *P<0.05; ***P<0.001. B, C57BL/6 mice were treated with 
antisense oligonucleotides (ASOs) and fed with HFD for 14 weeks. Hepatic pyruvate concentrations 
(B), plasma pyruvate concentrations (C), plasma lactate concentrations (D), hepatic PDH activity (E), 
and acetyl-CoA concentrations (F) were determined. G, Mouse primary hepatocytes were treated with 
G-control or G-(P)RR for 36 hours, and cellular Acetyl-CoA concentrations were determined. Three 
independent experiments in triplicates were performed. ***P<0.001. Oxygen consumption rate (OCR; 
H) and fuel dependency (I) were measured in mouse primary hepatocytes treated with G-control or 
G-(P)RR for 36 hours. Arrow 1 to 3 indicates addition of oligomycin, FCCP (carbonyl 
cyanide-4-[trifluoromethoxy] phenylhydrazone) and the mixture of rotenone and antimycin, 
respectively. n=6 per group. *P<0.05; ***P<0.001. FA indicates fatty acid; and N.S., not significant. 
Discussion 
We recently reported that the (P)RR is a novel modulator of LDL metabolism in 
vitro31. In the current study, we demonstrate that also in vivo, inhibiting the (P)RR in 
hepatocytes leads to defective LDL clearance as a result of reduced SORT1 and 
LDLR protein abundance. SORT1 is a recently identified hepatic clearance receptor 
for LDL, which also regulates VLDL secretion and plasma triglycerides16,20–22,38. 
SORT1 deficiency reduces VLDL secretion and plasma triglycerides,20 and in line 
with this, we found that (P)RR inhibition reduced VLDL secretion and plasma 
triglycerides, likely as a consequence of reduced SORT1. However, hepatic 
overexpression of hSORT1 in mice with (P)RR silencing was unable to prevent the 
reduction in plasma triglycerides, despite completely preventing the increase in 
plasma LDL-C. This implies that the (P)RR regulates plasma triglycerides via a 
SORT1-independent manner. Furthermore, plasma LPL activity was not affected by 
(P)RR inhibition, excluding the possibility that increased triglyceride hydrolysis 
accounts for the reduced plasma triglycerides. In fact, hepatic lipid concentrations, 
including triglycerides and cholesterol, were both markedly reduced by (P)RR 
inhibition, indicating that lipid synthesis is diminished. Indeed, we found that the 
protein abundance of ACC, the crucial enzyme catalyzing the first step in FA 
synthesis, was markedly reduced by (P)RR inhibition. As a consequence, limited 
amounts of lipid being available for ApoB lipidation likely caused the reduction in 
plasma triglycerides. This may also explain why (P)RR inhibition even reduced 
plasma cholesterol levels in LDLR-deficient mice, in whom SORT1-dependent LDL 
clearance is impaired. 
 
Our results raise the question of how the (P)RR regulates cellular lipid levels. 
Intriguingly, vacuolar H+-ATPase has recently been identified as a component of the 
mTORC1 (mechanistic target of rapamycin complex 1) pathway39. Indeed, 
acidification of lysosomes by vacuolar H+-ATPase is crucial for mTOR activation and 
function40. Increased mTORC1 activity is observed in genetic and HFD-induced 
obesity and has been implicated in the regulation of lipogenesis and VLDL 
secretion41–43. Knocking down the (P)RR reduces the protein levels of several 
subunits of the vacuolar H+-ATPase complex28–30,44. Consequently, (P)RR inhibition 
may prevent mTORC1 activation. Nevertheless, this seems unlikely as a recent report 
found that mTORC1 signaling was unaffected by (P)RR45. 
 
An alternative explanation for the effect of (P)RR on hepatic lipid metabolism may be 
related to the renin-angiotensin system, which has been linked with obesity and lipid 
metabolism46. However, this too seems unlikely, as the affinity of (P)RR to (pro)renin 
is very low, and in fact, their interaction requires supraphysiological concentrations of 
(pro) renin. Rather, by using a combined unbiased transcriptome and proteomic 
approach, we now identified PDH and ACC as downstream effectors of (P)RR 
inhibition. (P)RR inhibition has previously been reported to reduce PDHB protein 
levels via a tyrosine-phosphorylation–dependent manner in mouse retina and human 
retinal pigment epithelium cells47. We found that both PDHA and PDHB were 
reduced by (P)RR inhibition. PDH is a ubiquitously expressed enzyme complex that 
catalyzes the conversion of pyruvate to acetyl-CoA48,49, acting as a central node that 
links lipid metabolism, glucose metabolism, and the tricarboxylic acid cycle. We thus 
speculated that by reducing PDH protein abundance and activity, (P)RR inhibition 
would reduce acetyl-CoA production from glucose and consequently diminish FA 
synthesis and increase FA oxidation (Figure 7) 50. Indeed, this is what we observe in 
the livers of (P)RR-silenced mice. In addition, (P)RR inhibition also reduced ACC 
protein abundance. ACC plays an essential role in regulating FA synthesis and 
degradation37. Genetic deletion, or inhibition, of ACC reduces body weight gain and 
fat mass, suppresses triglycerides synthesis, and increases FA oxidation and energy 
expenditure51,52, which resembles the phenotype of hepatic (P) RR inhibition. 
Moreover, PPARγ (peroxisome proliferator-activated receptor gamma) expression 
was reduced by (P) RR inhibition by ≈50% (Online Figure VII), and this may also 
have contributed to the reduced hepatic lipogenesis, as hepatic PPARγ plays 
important roles in HFD-induced up-regulation of lipogenic genes and de novo 
lipogenesis53–55. Recent studies have reported that genetically deleting adipose (P)RR 
in mice resulted in resistance to diet-induced obesity56 and accelerated oxygen 
consumption57, yet causing severe hepatosteatosis.56 Unaltered (P)RR expression in 
both white adipose tissues and brown adipose tissues excluded the possibility that 
adipose (P)RR deficiency also contributed to the observed phenotype in our study. 
However, it raises the question whether inhibiting the (P)RR in both adipose tissue 
and liver would provide additional beneficial effects in treating metabolic disorders. 
 
Post-transcriptional regulation of ACC and PDH is not well understood, and thus, 
novel studies are required to fully understand their protein degradational regulation 
and the role of the (P)RR in this process. TRB3 (tribblesrelated protein 3) has been 
reported to control ACC degradation under fasting conditions by coupling ACC to the 
E3 ligase COP1 (constitutive photomorphogenic protein 1) 58. Interestingly, (P)RR 
inhibitions upregulated the expression of several E3 ligases, including HECTD1 
(HECT domain E3 ubiquitin protein ligase 1; Online Table III), and both ACCα and 
ACCβ have been reported to interact with HECTD159. It is therefore conceivable that 
(P)RR inhibition accelerates ACC degradation via lysosomes by upregulating 
HECTD1. Simultaneously, the (P)RR inhibition–induced reduction in PDH 
abundance is more difficult to understand. Inhibiting either autophagy, the lysosome 
or the proteasome, did not rescue this reduction, nor did inhibit mitophagy, a special 
form of autophagy involved in degradation of mitochondrial proteins (data not shown). 
This may suggest that (P)RR inhibition regulates PDH abundance via an as yet 
unsolved mechanism, as seems to be the case with SORT1 as well31.  
In conclusion, we report that hepatic (P)RR is a crucial regulator of lipid metabolism. 
Inhibiting hepatic (P)RR reduced ACC and PDH protein levels and consequently 
increases FA oxidation and reduces lipid synthesis, thus attenuating diet-induced 
obesity and liver steatosis, as well as improving glycemic controls in C57BL/6 mice. 
Taken together, our study highlights the potential of inhibiting hepatic (P)RR as a 
therapeutic treatment for metabolic disorders such as fatty liver diseases and familial 
hypercholesterolemia. 
  
Figure 7. Model for reprogrammed hepatic metabolism by (pro)renin receptor ([P]RR) inhibition. 
Inhibiting hepatic (P)RR reduces PDH (pyruvate dehydrogenase) activity, impairing pyruvate 
metabolism and reducing acetyl-CoA supply from pyruvate, which limits fatty acid (FA) biosynthesis. 
(P)RR inhibition further limits FA biosynthesis by reducing protein abundance of ACC (acetyl-CoA 
carboxylase), the crucial enzyme in FA biosynthesis. It further signals to increase FA oxidation via 
reduced malonyl-CoA, an inhibitor of FA oxidation that blocks the transportation of long-chain fatty 
acylcarnitine by carnitine acyltransferase I (CAT1). TCA indicates tricarboxylic acid. 
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Supplemental Materials 
Methods: 
Animals 
C57BL/6 mice and LDLR-/- mice were obtained from Model Animal Research Center 
of Nanjing University (Nanjing, China), and were housed at a 10-hour light/14-hour 
dark cycle. 8-week old male C57BL6 mice were injected weekly with saline, GalNAc 
control ASOs (G-conrol), or GalNAc (P)RR ASOs [G-(P)RR] subcutaneously. For 
experiments ≤ 4 weeks, ASOs were dosed at 3 mg/kg/week. For experiments ≥ 4 
weeks, ASOs were dosed at 3 mg/kg/week in the first 4 weeks, and were then reduced 
to 1.5 mg/kg/week until end of the experiment. Mice were either fed with ND (Harlan 
Teklad) or HFD (42% kcal fat, 0.2% cholesterol, Harlan Teklad). LDLR-/- mice were 
treated in the same way as C57BL/6 mice. Body weight was monitored weekly. Food 
consumption of each cage hosting 6 mice was recorded weekly. Blood samples were 
collected via submandibular bleeding after 6h fasting. Plasma lipid TC and TG levels 
were monitored bi-weekly, unless indicated elsewhere. Experimental procedures were 
approved by local animal ethnic committee (no. 2014-0140). 
 
Antisense Oligonucleotides (ASOs) 
ASOs with 5’-methyl modified cytosine and a phosphorothioate backbone containing 
2-O, 4-C-[(S)-ethylidene]- D-ribose (cEt) modified sugars were synthesized as 
described previously1. Chimeric ASOs containing 16mer cEt chemistries were used 
with the gapmer design of 3-10-3 wherein the terminal 5’ and 3’ nucleotides 
contained the cET modified sugars that flanked 10 nucleotides with unmodified 
sugars. The liver targeting conjugate GalNAc was connected through a 
trishexylamino-(THA)-C6 linker at the 5’ end of the ASO 2. Extensive in vitro 
activity screens were performed followed by in vivo tolerability and activity studies to 
identify the lead (P)RR ASO with the following nucleotide sequence 
AGATATTGGTCCATTT. A control ASO that did not hybridize to any known rodent 
mRNA was used and had the following nucleotide sequence, 
GGCCAATACGCCGTCA. 
 
Intraperitoneal glucose tolerance test (IPGTT) 
IPGTT was performed as described elsewhere3, one week prior to the end of the study. 
Briefly, following 16h fasting, 2 g/kg glucose was injected intraperitoneally to mice. 
Blood samples were collected from tail vain at 0, 15, 30, 60 and 120 min after glucose 
injection, and blood glucose was measured using a glucometer (Roche). Glucose 
levels at each time point were compared, and overall differences in glycemic control 
were compared using area under curve (AUC). 
 
In vivo LDL clearance assay 
In vivo LDL clearance was measured as described before4. In short, mice were 
injected with 50 μg human Dil-labeled LDL (AngYuBio, Shanghai) via a tail-vein. 
Then, blood samples were collected retro-orbitally at 2, 10, 20, 40, 80, 160, and 300 
min after injection. A standard curve was constructed by serial dilution of the human 
Dil-labeled LDL into mice plasma. Dil-LDL concentrations at 2 min after injection 
were the highest and were thus set as the baseline value for further analysis. 
Differences in VLDL secretion were compared using area under curve (AUC). 
 
Hepatic VLDL secretion 
To determine VLDL-TG secretion rate, mice were fasted for 4 hours and injected 
intraperitoneally with 1 mg/g Pluronic F127 (Sigma Aldrich), a detergent that inhibits 
lipolysis. Subsequently, blood samples were collected by retroorbital bleeding at 0, 1, 
2 and 4 hours after Pluronic F127 injection. Differences in VLDL secretion were 
compared using area under curve (AUC). 
 
Fast Protein Liquid Chromatography (FPLC) analysis of plasma lipoproteins 
FPLC analysis of plasma lipoproteins was performed as described before5. In short, 
plasma samples were pooled, and cleared by centrifugation and filtering through a 
0.22 μm filter. 200 μL cleared plasma samples were loaded for FPLC analysis using 
an AKTA purifier (GE) and Superose-6 Increase 10/300 GL (GE). Flow rate was set 
to 0.5 mL/min, and fractions between 10-16 mL were collected at intervals of 0.25 
mL/fraction. Cholesterol and triglycerides content in each fraction was measured. 
 
Oxygen consumption and physical activity measurement 
Metabolic and physical activity of the mice were measured using an indirect 
opencircuit calorimeter (Oxylet, Panlab) 6. Mice were housed individually in 
metabolic chambers and oxygen consumption, CO2 production, and physical activity 
were recorded at 30 min intervals for consecutive 48 hours. For accuracy, the 
recorded data from the first 12-14 hours after the mice have been housed in the 
chamber were not analyzed. 
 
Body composition analysis 
Fat and lean mass composition of the mice were evaluated by EchoMRI (Echo 
Medical Systems, Houston, TX, USA) before sacrifice. Weights of different fat 
tissues were measured using a scale balance with 0.0001-gram accuracy (Sartorius). 
 
H&E staining and Oil Red O staining 
Hematoxylin and eosin (H&E) staining was performed on 5 μm tissue sections which 
were Bouin’s-fixed and paraffin-embedded. Oil Red O staining was used to detected 
hepatic neutral lipids. Fresh liver and adipose tissues embedded in OCT were 
cryosectioned for 7 μm. After fixation with 4% paraformaldehyde, sections were 
stained with 0.3% oil red o following standard procedures7 and then counterstained 
with hematoxylin. Images were scanned using Cytation 5 Cell Imaging Multi-mode 
reader (Biotek). 
 
Measurement of ALT and AST 
Blood samples were precleared by centrifugation at 3,000×g for 5 minutes. Plasma 
alanine aminotransferase (ALT) and aspartate aminotransferase (AST) activities were 
measured by commercial kits (Biosino) following the manufacture’s protocol. 
 
Adenovirus and Adeno-associated virus 
Adeno-associated virus (AAV) expressing the D377Y PCSK9 mutant and their use 
was previously described8. Eight-week-old mice were intraperitoneally with 
AAV-PCSK9 at a concentration of 10×10 10 genomic copies, and fed a chow-diet for 
4 weeks to induce LDLR degradation. Afterwards, mice were treated with saline, 
G-control, or G-(P)RR for 4 weeks, and fed with chow or HFD. Human SORT1 under 
control of a CMV promotor was cloned and inserted in to pAd-EF1a-GFP vector 
(Vigenebio, China). Packaging of adenovirus was performed by linearization of the 
plasmid and transfection of 293A cells. Adenoviral particles were purified by 
ultracentrifugation, and virus titer was determined by serial dilution and plaque 
formation. 8-weeks old male mice were injected with 1.5×109 pfu Ad-hSORT1 or 
Ad-GFP (purchased from Vigenebio) via tail-vein. Mice were fed with chow or HFD 
for 7 days, and sacrificed after 6h fasting. 
 
Transcriptome analysis 
To assess whether silencing hepatic (P)RR affects gene expression in the liver, we 
injected mice (3 mice/group) intraperitoneally with saline or G -(P)RR as described 
above. After 5 days, the mice were sacrificed after 6h fasting, and liver samples were 
collected immediately and stored in Trizol at -80 °C until use. Total RNA was 
extracted and a RNA sequencing library was constructed for each sample using the 
Illumina Mrna-Seq Prep Kit. Paired-End libraries were prepared following Illumina’s 
protocols and sequenced on the Illumina HiSeq X10 platform. RNA Sequencing reads 
were analyzed following the reported protocol with HISAT, StringTie and Ballgown9. 
More specifically, high quality sequencing reads were firstly mapped to the mouse 
reference genome (version Ensembl GRCm38) using HISAT with default 
parameters10. Transcriptomic expression at gene and transcript level, characterized by 
FPKM (Fragments Per Kilobase of transcript per Million mapped reads), was then 
quantified by StringTie9. The Ballgown package was used to identify differential 
expressed genes (DEGs) with P <0.05 between G-(P)RR and saline control11. 
Functional analysis of all DEGs was preformed using DAVID functional annotation 
clustering tool12. Gene numbers were calculated for each Gene ontology (GO) 
category, and a hypergeometric test was used to identify significantly enriched GO 
categories in DEGs. 
 
Comparative proteomics using iTRAQ 
To understand how does (P)RR inhibition affects lipid metabolism and energy 
metabolism, we performed comparative proteomics analysis. Mice (n=3/group) were 
treated with G-control or G-(P)RR for 4 weeks, and fed with chow or HFD. Mice 
were sacrificed after 6h fasting. Livers were collected and homogenized in lysis 
buffer by TissueLyzer. Proteins were precipitated by acetone and resuspended with 
dissolving buffer containing 6 M guanidine hydrochloride and 300 mM TEAB 
(triethylammonium bicarbonate). Protein concentrations were determined by BCA, 
and equal amounts of proteins from individual samples per group were mixed and 
processed for iTRAQ labeling. Labeled samples were fractionated by high pH 
separation using Acquity UPLC H-Class Bio system (Waters Corporation, Milford, 
MA) connected to a reverse phase column (XBridge C18 column, 2.1 mm×150 mm, 
3.5 μm, 300 Å, Waters Corporation, Milford, MA). High pH separation was 
performed using a linear gradient, starting from 5% B to 35% B in 40 min (B: 5 mM 
ammonium formate in 90% acetonitrile, pH 10.0, adjusted with ammonium 
hydroxide). The column flow rate was maintained at 200 μL/min and column 
temperature was maintained at room temperature. Ten fractions were collected. Each 
fraction was dried in a vacuum concentrator for the next step. The peptide samples 
were resuspended with 30 μL solvent A respectively (A: water with 0.1% formic acid; 
B: acetonitrile with 0.1% formic acid), separated by nano-RPLC (EASY -nLC 1000, 
Thermo Fisher Scientific) and analyzed by online electrospray tandem mass 
spectrometry (Q Exactive mass spectrometer, Thermo Fisher Scientific). 5 μL peptide 
sample was loaded onto the trap column (Thermo Scientific Acclaim PepMap C18, 75 
μm × 2 cm), and subsequently separated on the analytical column (Acclaim PepMap 
C18, 75 μm × 15 cm) with a linear gradient, from 5% B to 35% B in 70 min, at a flow 
rate of 300 nL/min. The electrospray voltage of 1.6 kV versus the inlet of the mass 
spectrometer was used. The Q Exactive mass spectrometer was operated in the data 
-dependent mode to switch automatically between MS and MS/MS acquisition. 
Survey full -scan MS spectra (m/z 300 -1600) were acquired in Orbitrap with a mass 
resolution of 70,000 at m/z 200. The AGC target was set to 1 000 000, and the 
maximum injection time was 20 ms. The ten most intense peaks were isolated in the 
quadrupole with isolation window of 2.0 m/z units. Ions with charge states 2+, 3+, 
and 4+ were sequentially fragmented by higher energy collisional dissociation (HCD) 
with a normalized collision energy of 27%, fixed first mass was set at 100, and further 
analyzed in the Orbitrap mass analyzer with 17,500 resolution. The AGC target was 
set to 500,000, and the maximum injection time was 200 ms. In all cases, one 
microscan was recorded using dynamic exclusion of 35 seconds. 
 
The expression ratio [G-(P)RR/G -control] was calculated for each protein, under different 
diet conditions. Cut -off value was set to 1.2-fold [G-(P)RR/G-control >1.2 or <0.083]. 
Proteins with altered abundance were compared between HFD and chow, and only proteins 
that were regulated in the same trend by (P)RR inhibition were identified as differential 
expressed proteins (DEPs). Functional analysis of all DEGs was preformed using DAVID 
functional annotation clustering tool. Gene numbers were calculated for each Gene ontology 
(GO) category, and hypergeometric test was used to identify significantly enriched GO 
categories in DEGs. 
 
Measurement of pyruvate, acetyl-CoA, lactate and PDH activity 
Plasma pyruvate and lactate levels were detected using Pyruvate Assay kit (Sigma 
Aldrich) and Lactate Assay kit (Sigma Aldrich), following the manufacture’s 
protocols. To measure hepatic pyruvate, acetyl-CoA, and PDH activity, liver samples 
(~25 mg) were homogenized in the assay buffers provided with the kits, and 
measurements were performed according to the manufacture’s protocol. To measure 
cellular pyruvate levels, HepG2 cells were transfected with either control siRNA 
(siNC) or (P)RR siRNA [si(P)RR] for 48 hours. Cells were then detached using 
TrypLE and collected by centrifugation at 4 °C at 100x g, followed by washing with 
ice-cold PBS for three times. Measurement of pyruvate levels from an equal number 
of cells was performed according to manufacturer’s protocol, and normalized to cell 
number. Acetyl-CoA levels were measured using the PicoProbe Activity Microplate 
Assay kit (Abcam) in a similar approach, except that protein concentration was used 
to normalize acetyl-CoA levels. To measure lactate concentration, 24h after 
transfection, cells were switched to conditional medium (CM) that does not contain 
phenol red for 24 hours. Lactate levels in CM were then measured using the Lactate 
Assay kit (Sigma Aldrich). PDH activity was detected by a commercial kit (Sigma 
Aldrich), following the manufacture’s protocol. 
 
Measurement of lipoprotein lipase (LPL) activity 
Mice were treated with saline, G-control, or G-(P)RR and fed an HFD for 4 weeks. 
To measure LPL activity, mice were injected with 0.2 U/g heparin via tail-vein, and 
blood were drawn 15 min after heparin injection. Plasma LPL activity were then 
measured with a commercial kit from Abcam (catalog nr. ab204721). 
 
Measurement of plasma insulin 
Mice were treated with saline, G-control, or G -(P)RR and fed an HFD for 14 weeks. 
At 12th week, after 6-hour -fasting, plasma samples were collected and measured for 
insulin levels with an ultrasensitive mouse insulin ELISA kit from ALPCO (catalog 
nr. 80-INSMSU-E01), following the standard manufacturer’s protocol. 
 
Isolation and culture of primary hepatocytes 
Primary hepatocytes were isolated from C57BL/6J mice using previously described 
two-step collagenase perfusion method with modifications13. Briefly, mice were first 
perfused with O2 gassed perfusion buffer (5 mmol/L HEPES, 4 mmol/L KCl, 120 
mmol/L NaCl, 1 mmol/L KH2PO4, 2.4 mmol/L MgSO4, 40 mmol/L NaHCO3, 20 
mmol/L glucose) supplemented with 0.1 mmol/L EDTA, for 5-7 minutes at a constant 
flow rate at 7 mL/min. Perfusion path was set to flow into liver via inferior vena cava 
and flow out through portal vein. After the first perfusion step, mice were then 
perfused with O2 gassed perfusion buffer supplemented with 2.7 mmol/L CaCl2 and 
1.6 mg/mL Type IV collagenase (Sigma Aldrich, catalog nr. C5138), for 3 -4 minutes 
at a constant flow rate at 6 mL/min. Primary hepatocytes were released by removing 
liver capsule, and filtered through 100 µm filtered. Then, primary hepatocytes were 
washed with ice-cold DMEM and centrifuged at 50x g for 2 min, which was repeated 
for three times. Primary hepatocytes were seeded at a density of 600,000 cells/well or 
8,000 cells/well into collagen coated 6-well plate or Seahorse 24-well plate, 
respectively, and cultured with DMEM GlutaMax™ high glucose supplemented with 
5% FBS. To inhibit (P)RR expression in mouse primary hepatocytes, 0.05 mg/mL 
G-(P)RR ASO was added to culture medium 3 hours after seeding cells. 
 
Seahorse XFe24 analyzer 
HepG2 cells were seeded to Seahorse 24 -well plate, and cultured with DMEM 
GlutaMax™ high glucose with 10% FBS. HepG2 cells were transfected with siNC or 
si(P)RR for 48 hours. Mouse primary hepatocytes were isolated, seeded to Seahorse 
24 well plate, and cultured with DMEM GlutaMax™ high glucose supplemented with 
5% FBS. To inhibit (P)RR expression, mouse primary hepatocytes were treated with 
0.05 µg/mL final concentration of G-(P)RR ASOs for 36 hours. Mitochondrial 
function and cellular fuel dependency were then measured using Seahorse XF Cell 
Mito Stress Test Kit and Seahorse XF Mito Fuel Flex Test Kit, following 
manufacturer’s protocol, with the exception that for FA dependency assay oleic acid 
was added to a final concentration of 50 µmol/L to the cell culture medium 4 hours 
prior to the start of the assay. 
 
Immunoblotting 
For protein expression and phosphorylation studies, 50 mg mouse liver samples were 
homogenized in RIPA buffer (50 mM Tris-HCl, 150mM NaCl, 1% Triton X-100, 1% 
sodium deoxycholate, 0.1% SDS, pH 7.4) with phosphatase inhibitor cocktail (Sigma 
Aldrich) and protease inhibitors cocktail (Roche) using TissueLyzer (Qiagen). 
Homogenates were centrifuged at 10,000× g at 4 °C for 10 minutes to clear any cell 
debris or insoluble proteins. Protein concentrations were then determined using BCA 
assay (Pierce). Equal amounts of proteins (30-40 mg) were loaded and separated on 
4-20% Bis-Tris gels (GenScript), and transferred to PVDF membranes using iBlot® 2 
Dry Blotting System (Thermo Fisher Scientific). For high -molecular weight proteins 
such as acetyl-CoA carboxylase (ACC), samples were loaded and separated on 6% 
SDS -PAGE gels with ice-cold buffers for 3-5 hours, and transferred to PVDF 
membranes using traditional wet transferring system at 4 °C for 16 hours. The blots 
were then probed with the antibodies listed in Online Table Ⅰ and detected by 
ClarityTM Western Substrate (Bio-rad). The intensities of bands were analyzed using 
ImageJ. 
Online Table Ⅰ. Antibodies used in the study. 
Target 
Species 
originated Dilution Source Catalog number 
(P)RR Rabbit 1：1000 Sigma HPA003156 
SORT1 Mouse 1：1000 BD Bioscience 612100 
LDLR Rabbit 1：1000 Thermo Fisher Scientific PA5-22976 
PDHA Rabbit 1：1000 Proteintech 18068-1-AP 
PDHB Rabbit 1：1000 Proteintech 14744-1-AP 
ACC/ Rabbit 1：1000 Cell Signaling Technology 9957 
PPARγ Rabbit 1：1000 Cell Signaling Technology 2435 
Adiponectin Rabbit 1：1000 Cell Signaling Technology 2789 
β-actin Mouse 1：3000 Proteintech 60008-1 
 
RNA isolation and qPCR analysis 
Liver samples were homogenized with Trizol (Thermo Fisher Scientific) and total 
RNA was extracted using Direct-zolTM RNA MiniPrep kit (ZYMO Research). One 
microgram of total RNA was reverse transcribed with Prime ScriptTM RT Master 
Mix (TaKaRa). SYBR Green real-time quantitative PCR assays were performed on a 
qTOWER apparatus (Analytic Jena) using SYBR ®Premix Ex TaqTM II kit 
(TaKaRa). Primers used in the study were listed in Online Table Ⅱ. 
 
Hepatic lipids extraction and measurement 
To measure hepatic lipid contents, lipids in the liver were extracted using Folch’s 
method14. In short, 50 mg liver samples were homogenized using Tissue lyzer (60Hz, 
30s) in chloroform and methanol mixture (2:1) followed by adding methanol, 
chloroform and MQ. Extracted lipids were dried with N2 gas and dissolved with 
200µl PBS containing 1% Triton X-100. Cholesterol, triglycerides and non-esterified 
fatty acid (NEFA) were measured using colorimetric kits (Wako). 
 
Statistics 
All values were presented as mean ± SEM. For experiments with n number ≥ 8/group, 
D'Agostino-Pearson omnibus test was performed to test normality. For experiments 
with less n number, Kolmogorov -Smirnov test was performed for normality test. 
After passing normality test, one-way ANOVA followed by the Bonferroni test was 
performed for comparison of more than two groups. And student t-test was used to 
compare the differences between two groups. P values of <0.05 were considered 
significant. 
 
Online Table Ⅱ. List of qPCR primer sequences. 
Gene  sequence 
(P)RR 
Forward 5'-GGGTGGATAAACTGGCACTTC-3' 
Reverse 5'-TGGAATTTGCAACGCTGTC-3' 
SORT1 Forward 5'-TGAGGACATGGTCTTCATGC-3' 
Reverse 5'-GGTAAAGATGGTGCCAAACC-3' 
LDLR Forward 5'-GATGGCTATACCTACCCCTCAA-3' 
Reverse 5'-TGCTCATGCCACATCGTC-3' 
PDHA Forward 5'-GGCATCGTTGGAGCTCAG-3' 
Reverse 5'-ACAGACCTCATCTTTTCCATTGT-3' 
PDHB Forward 5'-GAGCTGAGATTTGTGCCAGA-3' 
Reverse 5'-ACATCAGCACCAGTGACACG-3' 
ACCα Forward 5'-GGCTCAAACTGCAGGTATCC-3' 
Reverse 5'-TTGCCAATCCACTCGAAGA-3' 
ACCβ Forward 5'-TGAATCTCACGCGCCTACTA-3' 
Reverse 5'-TTGTGTTCTCGGCCTCTCTT-3' 
PPARγ Forward 5'-GAAAGACAACGGACAAATCACC-3' 
Reverse 5'-GGGGGTGATATGTTTGAACTTG-3' 
Adiponectin Forward 5'-GGGGGTGATATGTTTGAACTTG-3' 
Reverse 5'-CTTTCCTGCCAGGGGTTC-3' 
UCP-1 Forward 5'-GGCCTCTACGACTCAGTCCA-3' 
Reverse 5'-TAAGCCGGCTGAGATCTTGT-3' 
Hadha Forward 5'-GAAATGGATAATATCTTGGCAAATC-3' 
Reverse 5'-TGGACGTCTTCATCAGAGGAG-3' 
Acaa2 Forward 5'-AAATGTGCGCTTCGGAAC-3' 
Reverse 5'-CGTTAATCCTGCCCACAAAG-3' 
Acadvl Forward 5'-GGTGGTTTGGGCCTCTCTA-3' 
Reverse 5'-TCCCAGGGTAACGCTAACAC-3' 
Acadl Forward 5'-GCTTATGAATGTGTGCAACTCC-3' 
Reverse 5'-CCGAGCATCCACGTAAGC-3' 
β-actin Forward 5'-CTAAGGCCAACCGTGAAAAG-3' 
Reverse 5'-ACCAGAGGCATACAGGGACA-3' 
 
 
 Online Figure Ⅰ. GalNAc-(P)RR ASO specifically targets hepatic (P)RR and affects plasma lipid 
concentrations. (A) Eight-weeks -old male C57BL6 mice were injected with saline (blue) or G-(P)RR 
(green). After 5 days, mice were sacrificed and tissues were collected and analyzed for (P)RR 
expression. (P)RR expression was normalized by the geometric mean of the expression of actin, 36B4 
and GAPDH. N=5/group; ***: p<0.001. (B) Immunoblotting of liver samples from saline or G-(P)RR 
treated mice. (C-E) (P)RR expression levels and protein abundance in epididermal white adipose tissue 
(eWAT), inguinal white adipose tissue (iWAT), and retroperitoneal white adipose tissue (rWAT) of 
mice treated with G-control or G-(P)RR for 14 weeks and fed with HFD. (F) (P)RR expression in 
brown adipose tissue (BAT) of mice treated with G-control or G-(P)RR for 14 weeks and fed with 
HFD. ( G) G-(P)RR did not affect mRNA levels of LDLR and SORT1. N=6 per group. (D) Plasma 
triglycerides and cholesterol concentration of C57BL6 mice injected with saline (blue), G-control 
(magenta) or G-(P)RR (green), and fed HFD for 14 weeks. N=10 per group. ***: p<0.001. G-control 
v.s G-(P)RR. (H) Plasma cholesterol levels of C57BL6 mice treated as indicated, and fed ND for 4 
weeks. N=12 per group. ***: p<0.001. G-control v.s G-(P)RR. 
 
 Online Figure Ⅱ. SORT1 overexpression does not prevent PRR deficiency induced reduction in 
LDLR protein levels in the liver. Eight-week-old male mice were treated with G-control or G-(P)RR, 
in combination of control adenovirus (Ad-GFP) or SORT1 expressing adenovirus (Ad-SORT1). N=6 
per mice. Representative blot. Ex: exogenously expressed hSORT1. En: endogenously expressed 
mSORT1. 
 
 
Online Figure Ⅲ . Inhibiting hepatic (P)RR in LDLR-/- mice reduces plasma cholesterol and 
triglyceride levels under both chow and HFD conditions. Eight-weeks-old male mice were treated with 
G-control (magenta) or G-(P)RR (green ), and fed with ND or HFD for 16 weeks. Plasma cholesterol 
levels (A&B) and plasma triglyceride levels (C&D) were monitored weekly in the first 4 weeks, and 
bi-weekly afterwards. N=8 per group. *: p<0.05; **: p<0.01; ***: p<0.001. 
 
  
Online Figure Ⅳ. Inhibiting the (P)RR reduces hepatic lipid levels under both ND and HFD 
conditions. Eight-week -old male mice were treated with saline (blue), G-control (magenta) or 
G-(P)RR (green ) for 4 weeks, fed ND or HFD. (A) Representative image of Oil Red O staining of 
liver samples. (B&C) Lipids were extracted from the liver using Folch’s method, and dried with N2 gas. 
Resuspended lipids were measured for triglycerides and cholesterol, normalized by the weight of liver 
samples used for lipid extraction. N=12 per group. *: p<0.05; ***: p<0.001. 
  
 
 Online Figure Ⅴ. Relevant information of hepatic (P)RR inhibition in C57BL6 mice fed HFD for 14 
weeks. Eight-week-old male mice were treated as indicated, and fed HFD for 14 weeks. (A) LW/BW 
ratio. LW/BW of C57BL6 mice at similar age, fed ND, was used as a reference value (n=6). N=10 per 
group. ***: p<0.001. (B) Percentage of fat and lean mass of total weight. (C) Representative image of 
H&E staining of inguinal white adipose tissue. (D) Plasma leptin concentrations. (E) Plasma 
adiponectin concentrations. (F) Fasting glucose levels of the mice were measured on week 12 of the 
HFD. (G) Intraperitoneal glucose tolerance test (IPGTT) was performed on week 13 of the HFD. 
Glucose levels at each time point were compared by One-way ANOVA and * indicates significant 
differences between G-control and G-(P)RR injected mice. AUC was used to compare the overall 
differences between groups. (H) Fasting plasma insulin levels at 12th week. (I) plasma ALT and AST 
activity, and AST/ALT ratio. N=10 per group; *: p<0.05; (J) accumulated food intake during 
experimental period, and accumulated food intake adjusted by end time body weight. SBP (K) and 
heart rate (L) measured 7 days prior to sacrifice. N=10 per group. (M) 24h average physical activity of 
G-control injected and G-(P)RR injected mice was monitored with a metabolic monitoring system 4 
days prior to sacrifice. N=8 per group. 
  
 Online Figure Ⅵ. GO enrichment analysis reveals that inhibiting the (P)RR extensively affects genes 
involved in metabolic processes. Analysis of transcriptome (A&B), or comparative proteomics (C&D). 
Top 20 enriched biological processes (BP) (A&C). Top 20 enriched KEGG pathways (B&D). 
  
 
Online Figure Ⅶ. Hepatic genes expression are affected by (P)RR inhibition. Eight-week-old male 
C57BL6 mice were treated with G-control or G-(P)RR, fed HFD for 14 weeks. Hepatic gene 
expressions were analyzed, and normalized by the expression of β-actin in the same sample. N=6 per 
group. *: p<0.05; **: p<0.01. 
 
 Online Figure Ⅷ. Silencing the (P)RR in HepG2 cells reduces ACC and PDH protein abundance 
resulting in increased oxygen consumption and dependency on fatty acid as fuel source. (A) (P)RR 
expression was silenced in HepG2 cells and a representative blot of 3 independent experiments in 
quadruplicate is shown. Total cell lysates were immunoblotted as indicated, and the level of PDHA, 
PDHB, and ACCα/β protein was quantified and normalized to the level of β-actin in the same lysate. 
***: p<0.001. ( B) HepG2 cells were transfected with control or (P)RR siRNAs for 48h. Cell were 
incubated with vehicle control, 100 nmol/L bafilomycin A1 (BafA1), 7.5 mmol/L 3-3-Methyladenine, 
and 20 μmol/L MG-132(R) for 8 hours. A representative blot of 4 independent experiments and 
corresponding quantification is shown. ( C-G) To measure cellular metabolites, HepG2 cells were 
transfected with control siRNA (siNC) or siRNA against (P)RR [si(P)RR] for 48 hours. Subsequently, 
cells or medium were prepared as described to measure intracellular acetyl-CoA levels (C), PDH 
activity (D), lactate levels in the conditional medium (CM) ( E), intracellular pyruvate levels (F), and 
intracellular triglyceride levels (G). Three independent experiments in triplicate were performed for 
each measurement and values were corrected with either the amount of protein or number of cells. N=9 
per group; *: p<0.05; ***: p<0.001. (H-I) Cellular oxygen consumption rates (OCR) (H) and fuel 
dependency (I) were measured in HepG2 cells treated with siNC or si(P)RR for 48 hours. Arrow 1-3 
indicates addition of oligomycin, FCCP and the mixture of rotenone and antimycin, respectively. N=6 
per group. *: p<0.05; **: p<0.01. 
  
 
 
 
 
 
 
References 
 
1. Seth PP, Siwkowski A, Allerson CR, Vasquez G, Lee S, Prakash TP, Kinberger G, Migawa 
MT, Gaus H, Bhat B, Swayze EE. Design, synthesis and evaluation of constrained 
methoxyethyl (cmoe) and constrained ethyl (cet) nucleoside analogs. Nucleic Acids Symp Ser 
(Oxf). 2008:553-554 
2. Prakash TP, Yu J, Migawa MT, et al. Comprehensive structure-activity relationship of 
triantennary n-acetylgalactosamine conjugated antisense oligonucleotides for targeted 
delivery to hepatocytes. J Med Chem. 2016;59:2718-2733 
3. Bowe JE, Franklin ZJ, Hauge-Evans AC, King AJ, Persaud SJ, Jones PM. Metabolic 
phenotyping guidelines: Assessing glucose homeostasis in rodent models. J Endocrinol. 
2014;222:G13-25 
4. Wagschal A, Najafi-Shoushtari SH, Wang L, et al. Genome-wide identification of 
micrornas regulating cholesterol and triglyceride homeostasis. Nat Med. 2015;21:1290-1297 
5. Roche-Molina M, Sanz-Rosa D, Cruz FM, Garcia-Prieto J, Lopez S, Abia R, Muriana FJ, 
Fuster V, Ibanez B, Bernal JA. Induction of sustained hypercholesterolemia by single 
adeno-associated virus-mediated gene transfer of mutant hpcsk9. Arterioscler Thromb Vasc 
Biol. 2015;35:50-59 
6. Franckhauser S, Munoz S, Elias I, Ferre T, Bosch F. Adipose overexpression of 
phosphoenolpyruvate carboxykinase leads to high susceptibility to diet-induced insulin 
resistance and obesity. Diabetes. 2006;55:273-280 
7. Thatcher SE, Zhang X, Howatt DA, Lu H, Gurley SB, Daugherty A, Cassis LA. 
Angiotensin-converting enzyme 2 deficiency in whole body or bone marrow-derived cells 
increases atherosclerosis in low-density lipoprotein receptor-/- mice. Arterioscler Thromb 
Vasc Biol. 2011;31:758-765 
8. Lu H, Howatt DA, Balakrishnan A, Graham MJ, Mullick AE, Daugherty A. 
Hypercholesterolemia induced by a pcsk9 gain-of-function mutation augments angiotensin 
ii-induced abdominal aortic aneurysms in c57bl/6 mice-brief report. Arterioscler Thromb 
Vasc Biol. 2016;36:1753-1757 
9. Pertea M, Kim D, Pertea GM, Leek JT, Salzberg SL. Transcript-level expression analysis 
of rna-seq experiments with hisat, stringtie and ballgown. Nat Protoc. 2016;11:1650-1667 
10. Kim D, Langmead B, Salzberg SL. Hisat: A fast spliced aligner with low memory 
requirements. Nat Methods. 2015;12:357-360 
11. Frazee AC, Pertea G, Jaffe AE, Langmead B, Salzberg SL, Leek JT. Ballgown bridges 
the gap between transcriptome assembly and expression analysis. Nat Biotechnol. 
2015;33:243-246 
12. Huang DW, Sherman BT, Tan Q, Kir J, Liu D, Bryant D, Guo Y, Stephens R, Baseler 
MW, Lane HC, Lempicki RA. David bioinformatics resources: Expanded annotation database 
and novel algorithms to better extract biology from large gene lists. Nucleic Acids Res. 
2007;35:W169-175 
13. Severgnini M, Sherman J, Sehgal A, Jayaprakash NK, Aubin J, Wang G, Zhang L, Peng 
CG, Yucius K, Butler J, Fitzgerald K. A rapid two-step method for isolation of functional 
primary mouse hepatocytes: Cell characterization and asialoglycoprotein receptor based assay 
development. Cytotechnology. 2012;64:187-195 
14. Folch J, Lees M, Sloane Stanley GH. A simple method for the isolation and purification 
of total lipides from animal tissues. J Biol Chem. 1957;226:497-509 
 
 
